ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Tevogen Bio’s CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer’s AI Discussion Panel

WARREN, N.J., March 07, 2025 (GLOBE NEWSWIRE) -- Mittul Mehta, Chief Information Officer & Head of Tevogen.AI at Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company, recently joined industry leaders at Proskauer’s AI discussion panel, "Attuned AI: Shaping AI to Empower Your Industry," held on March 6, 2025, in New York City.

Along with Mittul Mehta, the event featured Brooker Belcourt, General Manager of Finance from Perplexity, and Andrew Johnston, Strategic Business Development Manager from Harvey, to explore how AI is transforming the finance, biotech, and legal sectors. During the discussion, Mehta shared insights into Tevogen.AI’s pioneering approach to AI-driven advancements in biotech, highlighting practical applications, emerging trends, and strategies for leveraging AI to enhance precision medicine and operational efficiencies.

“As AI continues to reshape industries, it’s critical to tailor its potential to address the unique challenges and opportunities within each sector. At Tevogen.AI, we are committed to leveraging AI to accelerate innovation in precision medicine, making advanced therapies more accessible and affordable,” said Mehta.

The event, moderated by Proskauer Partner Wai Choy, a leader of the international law firm’s AI Practice, Technology, Media & Telecommunications Group and Life Sciences Group, featured an engaging conversation on the latest AI advancements and strategies, followed by a networking reception attended by industry professionals and thought leaders.

“It has been exciting to see Tevogen.AI combine its carefully curated proprietary datasets with its innovative application of generative AI models to derive valuable insights that are optimized for the specific needs of biotech discovery and development,” said Choy.

For more information, please visit Tevogen.AI

About Tevogen Bio

Tevogen Bio is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies to treat infectious disease and cancers, aiming to address the significant unmet needs of large patient populations. Tevogen Bio leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen Bio has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence.

Tevogen Bio is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen Bio’s leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation.

Contacts

Tevogen Bio Communications

T: 1 877 TEVOGEN, Ext 701

Communications@Tevogen.com

A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/26077bb6-b115-49b2-93ce-5839e3f83af6


Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.